Pascal Deschatelets, Chief Scientific Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 2,296 shares at $67.77 ($156K) on 2024-02-12, disclosed to the SEC on 2024-02-13.
Seasonal sale ($156k) by Chief Scientific Officer — this insider has traded APLS in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $67.77 | 1,148 | $78K | 50.0% |
| 2 | $67.77 | 1,148 | $78K | 50.0% |
| Total | $67.77 avg | 2,296 | $156K | 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $51K | — | Filing → |
| APLS | SELL | 2025-01-30 | $24K | — | Filing → |
| APLS | SELL | 2025-01-23 | $240K | — | Filing → |